Chikungunya virus infection prevalence in Africa

a contemporaneous systematic review and meta-analysis

F. B.N. Simo, J. J. Bigna, E. A. Well, S. Kenmoe, F. B.Y. Sado, Scott Weaver, P. F. Moundipa, M. Demanou

Research output: Contribution to journalReview article

Abstract

Objectives: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). Study design: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. Methods: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95% confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. Results: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0%), seven (18.0%) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7% (95% CI 3.0–19.6; 16 studies) and 16.4% (95% CI 9.1–25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). Conclusions: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalPublic Health
Volume166
DOIs
StatePublished - Jan 1 2019

Fingerprint

Meta-Analysis
Seroepidemiologic Studies
Neglected Diseases
Immunoglobulin M
Immunoglobulin G
Confidence Intervals
Epidemiology
Chikungunya virus
Southern Africa
Northern Africa
PubMed
MEDLINE
Health Personnel
Observational Studies
Disease Outbreaks
Chikungunya Fever
Fever
Public Health
Research Personnel

Keywords

  • Africa
  • Arbovirus
  • Chikungunya
  • Epidemiology

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Chikungunya virus infection prevalence in Africa : a contemporaneous systematic review and meta-analysis. / Simo, F. B.N.; Bigna, J. J.; Well, E. A.; Kenmoe, S.; Sado, F. B.Y.; Weaver, Scott; Moundipa, P. F.; Demanou, M.

In: Public Health, Vol. 166, 01.01.2019, p. 79-88.

Research output: Contribution to journalReview article

Simo, FBN, Bigna, JJ, Well, EA, Kenmoe, S, Sado, FBY, Weaver, S, Moundipa, PF & Demanou, M 2019, 'Chikungunya virus infection prevalence in Africa: a contemporaneous systematic review and meta-analysis', Public Health, vol. 166, pp. 79-88. https://doi.org/10.1016/j.puhe.2018.09.027
Simo, F. B.N. ; Bigna, J. J. ; Well, E. A. ; Kenmoe, S. ; Sado, F. B.Y. ; Weaver, Scott ; Moundipa, P. F. ; Demanou, M. / Chikungunya virus infection prevalence in Africa : a contemporaneous systematic review and meta-analysis. In: Public Health. 2019 ; Vol. 166. pp. 79-88.
@article{bd8e6f8cc5644ccda9552516669721fa,
title = "Chikungunya virus infection prevalence in Africa: a contemporaneous systematic review and meta-analysis",
abstract = "Objectives: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). Study design: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. Methods: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95{\%} confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. Results: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0{\%}), seven (18.0{\%}) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7{\%} (95{\%} CI 3.0–19.6; 16 studies) and 16.4{\%} (95{\%} CI 9.1–25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). Conclusions: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.",
keywords = "Africa, Arbovirus, Chikungunya, Epidemiology",
author = "Simo, {F. B.N.} and Bigna, {J. J.} and Well, {E. A.} and S. Kenmoe and Sado, {F. B.Y.} and Scott Weaver and Moundipa, {P. F.} and M. Demanou",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.puhe.2018.09.027",
language = "English (US)",
volume = "166",
pages = "79--88",
journal = "Public Health",
issn = "0033-3506",
publisher = "Elsevier",

}

TY - JOUR

T1 - Chikungunya virus infection prevalence in Africa

T2 - a contemporaneous systematic review and meta-analysis

AU - Simo, F. B.N.

AU - Bigna, J. J.

AU - Well, E. A.

AU - Kenmoe, S.

AU - Sado, F. B.Y.

AU - Weaver, Scott

AU - Moundipa, P. F.

AU - Demanou, M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). Study design: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. Methods: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95% confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. Results: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0%), seven (18.0%) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7% (95% CI 3.0–19.6; 16 studies) and 16.4% (95% CI 9.1–25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). Conclusions: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.

AB - Objectives: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). Study design: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. Methods: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95% confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. Results: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0%), seven (18.0%) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7% (95% CI 3.0–19.6; 16 studies) and 16.4% (95% CI 9.1–25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). Conclusions: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.

KW - Africa

KW - Arbovirus

KW - Chikungunya

KW - Epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85056858583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056858583&partnerID=8YFLogxK

U2 - 10.1016/j.puhe.2018.09.027

DO - 10.1016/j.puhe.2018.09.027

M3 - Review article

VL - 166

SP - 79

EP - 88

JO - Public Health

JF - Public Health

SN - 0033-3506

ER -